HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
|
|
- Kerrie Martin
- 5 years ago
- Views:
Transcription
1 HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University of Illinois at Chicago, College of Pharmacy 1 Immunology of HIV 2 1
2 Learning Objectives At the conclusion of this presentation, participants will be able to: 1. Describe the basic immunology and impact of HIV 1 and HIV 2 2. Identify symptomatology associated with acute HIV infection 3. Explain effects of untreated HIV on the body 3 HIV 1 vs. HIV 2 1 HIV 1 Higher infectivity Lower CD4 counts Higher viral loads Shorter asymptomatic phase Shorter time to AIDS progression HIV RNA used to monitor ART efficacy CD4 recovery cells/mm 3 annually Lower infectivity Higher CD4 counts Lower viral loads HIV 2 Prolonged asymptomatic phase Longer time to AIDS progression Cannot use HIV RNA levels to monitor ART efficacy in HIV 2 Poor CD4 recovery 1. Clin Infect Dis 2011;52(6):
3 *Full sized version of infographic available at end of handout 5 Source: AIDSinfo CD4 Count 1 Major indicator of immune function Type of lymphocyte (T helper cells) Most recent CD4 count is best predictor of disease progression CD4 count usually is the important consideration in decision to start antiretroviral therapy (ART) Recommended to offer treatment to ALL regardless of CD4 count cells/mm 3 = Normal Range < 200 cells/mm 3 = AIDS CD4 count may fluctuate from day to day and in response to stress, other infection(s), vaccination, fatigue, time of day agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at 6 3
4 CD4 Monitoring 1 Check at baseline and at least every 3 6 months During first 2 years of ART or if viremia develops while patient on ART or CD4 count <300 cells/mm 3 If patient is clinically stable, may consider checking annually After 2 years on ART with consistently suppressed viral load: CD cells/mm 3 CD4 count > 500 cells/mm 3 : CD4 monitoring is optional Important in determining response to ART Adequate response: CD4 increase cells/mm³ per year agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at 7 HIV RNA 1 Commonly referred to as viral load Detects HIV RNA in the serum (Tests for the virus, not the antibodies) Critical in determining response to ART Goal of ART: HIV RNA below limit of detection (< 20 copies/ml) Undetectable viral load indicates virologic suppression RNA monitoring Immediately prior to initiating therapy 2 8 weeks after start or change of ART Check at baseline and at least every 6 months in stable patients 8 4
5 Immune Response to HIV 1 Those with HIV will mount an effective immune response during the first few months of infection Over time this response will prove ineffective Cellular response Humoral response Production of HIV Antibodies 9 HIV Progression 1 Infected CD4 (T cells) can be found in draining lymph nodes within 2 days and in plasma within 5 days A rapid rise in viremia occurs during acute infection Occurs within days of the infection high viral load and dissemination to organs and central nervous system (CNS) During the acute phase of infection, symptomatic illness characterized by maculopapular rash and flu like symptoms After this phase, viral load is markedly reduced and reaches steady state levels 1. Reitz MS, Gallo RC. Human Immunodeficiency Viruses. In Mandell: Bennett JC, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett s: Principles and Practice of Infectious Disease, Vol 2, 8th ed. Philadelphia, PA: Elsevier; 2014:
6 Clinical Signs and Symptoms of HIV 11 Acute Infection 1 May be asymptomatic May become symptomatic 2 4 weeks after infection Fever, rash, lymphadenopathy, headache, diarrhea, oral ulcers, myalgia, or arthralgia Highly infectious during the acute infection phase and symptoms mimic other viral disease states 12 6
7 Acute Infection Symptoms Source: px Symptoms_of_acute_HIV_infection.png 13 Primary HIV Infection 1 1 to 3 months post transmission Peak in HIV RNA and decline in CD4 cells in the blood HIV can replicate during early infection without being controlled by the immune system Antibody development 3 to 12 weeks after infection Symptoms of seroconversion may develop and viral load decreases 14 7
8 Clinical Latency 1 Viral symptoms disappear May last as long as 10 years without ART Post acute phase, CD4 count increases in the blood again HIV RNA in plasma declines 15 AIDS 1 Acquired Immunodeficiency Syndrome After clinical latency period Rapid increase in HIV RNA Decline in CD4 counts AIDS: CD4 < 200 cells/mm 3 Risk for opportunistic infections, cancer, and death 16 8
9 AIDS Symptoms Source: Symptoms_of_AIDS.svg.png 17 Clinical Progression of HIV to AIDS 18 Source: content/uploads/2010/02/hiv_course.png 9
10 Effects of Untreated HIV 19 Effects of Untreated HIV on the Body 1 Without treatment immunosuppression leading to AIDS defining illnesses premature death Untreated HIV Immune deficiency Direct effect on end organs Indirect effects of associated inflammation on these organs 20 10
11 HIV Associated Nephropathy (HIVAN) 1 Most common cause of chronic kidney disease in HIVinfected individuals end stage kidney disease May occur at any CD4 count Almost exclusively in black patients Ongoing viral replication appears to be directly involved in renal injury Uncommon in virologically suppressed patients ART in patients with HIVAN Preserves renal function Prolongs survival 21 Co infection with Hepatitis B (HBV) and/or Hepatitis C Virus (HCV) 1 HIV infected individuals have more rapid progression of hepatitis related liver disease ART may slow liver disease progression Tenofovir, emtricitabine, and lamivudine active against HIV/HBV co infection Preservation or restoration of immune function Reducing HIV related immune activation and inflammation HCV treatment outcomes improve when HIV replication is controlled or CD4 counts are increased Early initiation of HIV treatment in the co infected population may reduce the risk of liver disease progression agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at
12 HIV/AIDS and Cardiovascular Disease (CVD) 1 Major cause of morbidity and mortality One third of serious non AIDS conditions 10% of deaths Higher rates of CVD risk factors Smoking Dyslipidemia Exposure to certain ARVs ART associated with improved markers of inflammation, immune function, coagulation, and endothelial function Low CD4 nadir, on therapy CD4 count, and treatment interruption linked to CVD Early initiation of ART to reduce viral replication reduces CV events 1. NIH Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at 23 Malignancy 1 Chronic infection associated with increased AIDS defining malignancies and non AIDSdefining malignancies Increased risk with CD4 < cells/mm 3 Protective effect of ART for HIV associated immunodeficiency Suppress viral replication Maintain CD4 count > cells/mm 3 1. NIH Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at
13 Neurologic Impact 1 HIV detected in cerebrospinal fluid (CSF) of untreated patients, yet patients typically asymptomatic May progress to HIV encephalitis or HIV associated dementia (HAD) More advanced systemic HIV infection severe CNS opportunistic infections (OIs) high morbidity and mortality Effective and early initiation of ART has significantly reduced neurological manifestations Reduction of CSF HIV RNA to undetectable levels Potential for HIV associated polyneuropathy Effective and early ART may reduce the effects NIH Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV 1 infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services: AIDSInfo. Available at Summary Although a cure does not exist, HIV is a retrovirus that is a controllable chronic disease state HIV can affect multiple organ systems throughout the body 26 13
When to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationDidactic Series. Primary HIV Infection. Greg Melcher, M.D. UC Davis AETC 8 Nov 2012
Didactic Series Primary HIV Infection Greg Melcher, M.D. UC Davis AETC 8 Nov 2012 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council
More informationDarunavir STADA 400, 600 and 800 mg film-coated tablets , Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Darunavir STADA 400, 600 and 800 mg film-coated tablets 7.9.2016, Version 1.1 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human
More informationSummary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Human immunodeficiency virus (HIV) attacks the cells of the immune system, the body's natural defense against germs and other
More informationPROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV
PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis
More information0% 0% 0% Parasite. 2. RNA-virus. RNA-virus
HIV/AIDS and Treatment Manado, Indonesia 16 november HIV [e] EDUCATION HIV is a 1. DNA-virus 2. RNA-virus 3. Parasite 0% 0% 0% DNA-virus RNA-virus Parasite HIV HIV is a RNA-virus. HIV is an RNA virus which
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationImmunodeficiencies HIV/AIDS
Immunodeficiencies HIV/AIDS Immunodeficiencies Due to impaired function of one or more components of the immune or inflammatory responses. Problem may be with: B cells T cells phagocytes or complement
More informationPART II! IMMUNE SENESCENCE!
PART II! IMMUNE SENESCENCE! IMMUNE SENESCENCE! RESEARCH IN HIV Background Senescence: the state of being old or the process or aging Immune senescence: the immune system profile seen in the elderly Does
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationThe how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?
Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection
More informationWhat Does HIV Do to You?
What Does HIV Do to You? HIV and the immune system Your immune system is supposed to protect you from viruses and other infections. Why, then, doesn t it protect you from HIV? The answer is complicated,
More informationNatural history of HIV Infection
HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment
More informationHIV/AIDS MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: HIV/AIDS MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN HIV/AIDS MEASURES GROUP: #159. HIV/AIDS: CD4+ Cell Count or CD4+ Percentage Performed #160. HIV/AIDS: Pneumocystis
More informationClinical Manifestations of HIV
HIV Symptoms Diane Havlir, MD Professor of Medicine and Chief, HIV/AIDS Division University of California, San Francisco (UCSF) WorldMedSchool; July 2, 2013 1 Clinical Manifestations of HIV! Result from
More informationThe effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors
The effect of lamivudine- versus tenofovir-containing antiretroviral regimen on hepatitis B infection in a cohort of HIV infected long term survivors Aura Temereanca 1,2, Luminita Ene 3, Adelina Rosca
More informationImportant Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)
Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil
More informationHIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
More informationHIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018
HIV: What Every Clinician Needs to Know ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING CONFERENCE BETTIE COPLAN MARCH 2018 Overview Overview recent trends in HIV incidence in the U.S. HIV screening
More informationMID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.
Life Cycle Diagnosis and Pathogenesis Scott M. Hammer, M.D. -1 Virion Entry Life Cycle of Entry -1 virion -1 Virus virion envelope Cell membrane receptor RELEASE OF PROGENY VIRUS REVERSE Co- TRANSCRIPTION
More informationMedical Overview March 7, Nina Lambert, NP Inova Juniper Program
Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who
More informationFayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES
1 of 7 I. Viral Origin. A. Retrovirus - animal lentiviruses. HIV - BASIC PROPERTIES 1. HIV is a member of the Retrovirus family and more specifically it is a member of the Lentivirus genus of this family.
More informationHIV-HBV coinfection in HIV population horizontally infected in early childhood between
UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA FACULTY OF MEDICINE HIV-HBV coinfection in HIV population horizontally infected in early childhood between 1987-1990 Supervising professor: Prof. Cupşa Augustin
More informationThe Struggle with Infectious Disease. Lecture 6
The Struggle with Infectious Disease Lecture 6 HIV/AIDS It is generally believed that: Human Immunodeficiency Virus --------- causes ------------- Acquired Immunodeficiency Syndrome History of HIV HIV
More informationHIV A 2017 Update Bill Rooney MD SCOR Global Life
NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing
More informationReport Back from CROI 2010
Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco
More informationHuman Immunodeficiency Virus. Acquired Immune Deficiency Syndrome AIDS
Human Immunodeficiency Virus Acquired Immune Deficiency Syndrome AIDS Sudden outbreak in USA of opportunistic infections and cancers in young men in 1981 Pneumocystis carinii pneumonia (PCP), Kaposi s
More informationHIV and Public Health: the Basics
HIV and Public Health: the Basics Joy Zeh, RN, MS, Family Nurse Practitioner VCU HIV/AIDS Center HIV and Public Health: the Basics Epidemiology Related Infections and Co-Morbidities Spectrum of HIV Infection
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationHIV-1 Dual Infection and Neurocognitive Impairment
HIV-1 Dual Infection and Neurocognitive Impairment Gabriel Wagner, MD Assistant Professor of Medicine Infectious Diseases & Global Public Health UC San Diego HIV-Associated End Organ Damage Antiretroviral
More informationMeasles, Mumps and Rubella. Ch 10, 11 & 12
Measles, Mumps and Rubella Ch 10, 11 & 12 Measles Highly contagious viral illness First described in 7th century Near universal infection of childhood in prevaccination era Remains the leading cause of
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationBody & Soul. Research update, 25 October 2016
Body & Soul Research update, 25 October 2016 Updates from BHIVA conference on... Cure breakthrough or not? Long acting retrovirals what do they offer? When to start treatment asap post diagnosis? Media
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationSysmex Educational Enhancement and Development No
SEED Haematology No 1 2015 Introduction to the basics of CD4 and HIV Viral Load Testing The purpose of this newsletter is to provide an introduction to the basics of the specific laboratory tests that
More information2016: The State of HIV & Hepatitis C in the District
2016: The State of HIV & Hepatitis C in the District Travis A. Gayles, MD, PhD Chief Medical Officer, HIV/AIDS, Hepatitis, STD, and TB Administration Division Chief, STD and TB Control February 29, 2016
More informationClinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation
ISPUB.COM The Internet Journal of Infectious Diseases Volume 6 Number 2 Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation Y Graza,
More informationHIV Update For the Internist
HIV Update For the Internist Disclosures I declare that I have received no incentives, financial or otherwise, from pharmaceutical or biomedical companies relevant to the content of this talk. As an Infectious
More informationMODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM
MODULE 3 FLORIDA DEPARTMENT OF HEALTH STUDY GUIDE HIV/AIDS: 101 WEMAKETHECHANGE.COM MODULE 3 SERVICE NEEDS FOR HIV-INFECTED INDIVIDUALS There are compelling personal and public health benefits to getting
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationSummary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat)
EMA/608280/2014 Summary of the risk management plan (RMP) for Rezolsta (darunavir / cobicistat) This is a summary of the risk management plan (RMP) for Rezolsta, which details the measures to be taken
More informationEmtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers
Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Training Guide for Healthcare Providers About emtricitabine/tenofovir disoproxil fumarate for HIV-1 PrEP
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationIsolated Hepatitis B Core Antibody
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014 Isolated Core Antibody Virology & terminology Definition
More informationDiagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know
Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know Carolyn K. Burr, EdD, RN Co-Clinical Director Deputy Director François-Xavier Bagnoud Center December 17 th, 2013
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationProgress against the HIV Epidemic: is the end in sight?
Progress against the HIV Epidemic: is the end in sight? Christine Hughes, BscPharm, PharmD, FCSHP Professor, Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Clinical Pharmacist, Northern
More informationGeneral HIV/AIDS Information
General HIV/AIDS Information The History of HIV In the summer of 1981, physicians in San Francisco observed that young, previously healthy homosexual men were developing an unusual type of pneumonia which
More informationDidactic Series. Immunizations in HIV Infected Individuals. Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017
Didactic Series Immunizations in HIV Infected Individuals Daniel Lee, MD UC San Diego, Owen Clinic 5/11/2017 Slides author: Ankita Kadakia, MD, AAHIVS 1 Learning Objectives To learn how vaccines induce
More informationVirology Introduction. Definitions. Introduction. Structure of virus. Virus transmission. Classification of virus. DNA Virus. RNA Virus. Treatment.
DEVH Virology Introduction Definitions. Introduction. Structure of virus. Virus transmission. Classification of virus. DNA Virus. RNA Virus. Treatment. Definitions Virology: The science which study the
More informationClinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals
Clinical Outcomes of Single Tablet vs. Multi-Tablet Antiretroviral Regimens in HIV-Infected Individuals Abstract #18 IRB Approved Jeannie Ong, Pharm.D., AAHIVP PGY2 HIV Pharmacotherapy Resident University
More informationImmunity and Infection. Chapter 17
Immunity and Infection Chapter 17 The Chain of Infection Transmitted through a chain of infection (six links) Pathogen: Disease causing microorganism Reservoir: Natural environment of the pathogen Portal
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationBiology 3201 Unit 2 Reproduction: Sexually Transmitted Infections (STD s/sti s)
Biology 3201 Unit 2 Reproduction: Sexually Transmitted Infections (STD s/sti s) STI s once called venereal diseases More than 20 STIs have now been identified most prevalent among teenagers and young adults.
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationComparison of Drug Treatment Protocols for Children Infected with HIV in Washington, DC and Cape Town, South Africa in Relation to NIH Guidelines
Comparison of Drug Treatment Protocols for Children Infected with HIV in Washington, DC and Cape Town, South Africa in Relation to NIH Guidelines Mariah M. Marshall Department of Human Science Georgetown
More informationThe Neurology of HIV Infection. Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University
The Neurology of HIV Infection Carolyn Barley Britton, MD, MS Associate Professor of Clinical Neurology Columbia University HIV/AIDS Epidemiology World-wide pandemic, 40 million affected U.S.- Disproportionate
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationFrailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi
Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationSupervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis.
Supervised Treatment Interruption (STI) in an Urban HIV Clinical Practice: A Prospective Analysis. J.L. YOZVIAK 1, P. KOUVATSOS 2, R.E. DOERFLER 3, W.C. WOODWARD 3 1 Philadelphia College of Osteopathic
More informationTreatment of HIV-1 in Adults and Adolescents: Part 2
Treatment of HIV-1 in Adults and Adolescents: Part 2 Heather E. Vezina, Pharm.D. University of Minnesota Laboratory Medicine & Pathology Experimental & Clinical Pharmacology wynnx004@umn.edu Management
More informationHIV 101: Fundamentals of HIV Infection
HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationBBS2711 Virology. Central Nervous System (CNS) Viruses. Dr Paul Young, Department of Microbiology & Parasitology.
BBS2711 Virology Central Nervous System (CNS) Viruses Dr Paul Young, Department of Microbiology & Parasitology. p.young@mailbox.uq.edu.au Viruses of the CNS Many human pathogenic viruses are capable of
More informationNo Conflict of Interest
No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand
More information, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic
1 Two attributes make AIDS unique among infectious diseases: it is uniformly fatal, and most of its devastating symptoms are not due to the causative agent Male to Male sex is the highest risk group in
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationABACAVIR HYPERSENSITIVITY REACTION
ABACAVIR HYPERSENSITIVITY REACTION Key Risk Minimisation Points: Abacavir Hypersensitivity Reaction (HSR) Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterised by fever
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology HIV is a virus that attacks the immune system (the body s natural defences) and weakens it by destroying certain white blood cells
More informationRisk Management Plan Summary
Risk Management Plan Summary EDURANT (rilpivirine) 25 mg film-coated tablet Document Version: 1.0 Document Date: 30.10.2017 Based on EU RMP version 7.0 Marketing authorization holder: Janssen-Cilag AG,
More informationHIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018
HIV/AIDS Today: What you need to know when providing services to individuals with HIV/AIDS (Part One) Presented live August 7, 2018 Mary McCarty-Arias, M.A., CRC More than 25 years experience training
More informationHuman Immunodeficiency Virus
Human Immunodeficiency Virus Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Viruses and hosts Lentivirus from Latin lentis (slow), for slow progression of disease
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationMedChem 401~ Retroviridae. Retroviridae
MedChem 401~ Retroviridae Retroviruses plus-sense RNA genome (!8-10 kb) protein capsid lipid envelop envelope glycoproteins reverse transcriptase enzyme integrase enzyme protease enzyme Retroviridae The
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationpatients with blood borne viruses Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled Document Lead:
CONTROLLED DOCUMENT Procedure for the management of patients with blood borne viruses CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Version Number: 4 Controlled Document Sponsor: Controlled
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationBasic facts about HIV and AIDS
Basic facts about HIV and AIDS Tiia Pertel Department of Public Health, University of Tartu Estonian Association of Sexual Health HIV the Human Immunodeficiency Virus) RNA-virus, belongs into the the family
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationChapter 38- Immune System
Chapter 38- Immune System First Line of Defense: Barriers Nonspecific defenses, such as the skin and mucous membranes, are barriers to potential pathogens. In addition to being a physical barrier to pathogens,
More informationHIV Basics: Pathogenesis
HIV Basics: Pathogenesis Michael Saag, MD, FIDSA University of Alabama, Birmingham Director, Center for AIDS Research ACTHIV 2011: A State-of-the-Science Conference for Frontline Health Professionals Learning
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More informationANTIRETROVIRAL THERAPY
ANTIRETROVIRAL THERAPY Editor s Note: Section III: Deciding When to Initiate ART is currently under revision due to recent data in favor of further expanding indications for antiretroviral therapy. What
More informationExtensive Kaposi's sarcoma in a HIV positive patient: A case report
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 1 Extensive Kaposi's sarcoma in a HIV positive patient: A case report G Lopez, Y Graza Citation G Lopez, Y Graza.. The Internet Journal
More informationHIV IN OKLAHOMA MAKING A DIFFERENCE
HIV IN OKLAHOMA MAKING A DIFFERENCE Madhuri Lad, DO, FACOI, AAHIVS Assistant Program and Medical Director OSU Internal Medicine Specialty Services HIV Program Clinical Assistant Professor Rashes Demographics
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationErrors in Dx and Rx of TB
Errors in Dx and Rx of TB David Schlossberg, MD, FACP Professor of Medicine Temple University School of Medicine Medical Director, TB Control Program Philadelphia Department of Public Health TB Still a
More information17a. Sexually Transmitted Diseases and AIDS. BIOLOGY OF HUMANS Concepts, Applications, and Issues. Judith Goodenough Betty McGuire
BIOLOGY OF HUMANS Concepts, Applications, and Issues Fifth Edition Judith Goodenough Betty McGuire 17a Sexually Transmitted Diseases and AIDS Lecture Presentation Anne Gasc Hawaii Pacific University and
More informationINTEGRATING HIV INTO PRIMARY CARE
INTEGRATING HIV INTO PRIMARY CARE ADELERO ADEBAJO, MD, MPH, AAHIVS, FACP NO DISCLOSURE 1.2 million people in the United States are living with HIV infection and 1 in 5 are unaware of their infection.
More informationHIV depletes T-helper17, we simply stimulate it. By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I.
HIV depletes T-helper17, we simply stimulate it By Prof. Dr.Pichaet Wiriyachitra Ph.D., F.R.A.C.I. Natural Healthcare for HIV infected HIV depletes T-helper17, we simply stimulate it Dr.Pichaet Wiriyachitra
More informationElements for summary tables in the EPAR
VI.1 Elements for summary tables in the EPAR VI.1.1 Summary table of Safety concerns The following risks are defined with the EU reference product: Table 2. Summary of safety concerns Important identified
More informationMYTHS OR FACTS OF STI s True or False
Viral STI s MYTHS OR FACTS OF STI s True or False 1. There is no cure for herpes or AIDS. 2. Condoms protect against STI s. 3. If two people are free from STI s and have no other sexual partners, they
More informationMeasles and Measles Vaccine
Measles and Measles Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases Note to presenters: Images of vaccine-preventable diseases are available from the Immunization Action Coalition
More informationIschemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection
HIV/AIDS MAJOR ARTICLE Ischemic Cardiovascular Disease in Persons with Human Immunodeficiency Virus Infection Max H. David, 1,3 Richard Hornung, 2 and Carl J. Fichtenbaum 1 1 Department of Medicine, Division
More informationClinical Aspect and Application of Laboratory Test in Herpes Virus Infection. Masoud Mardani M.D,FIDSA
Clinical Aspect and Application of Laboratory Test in Herpes Virus Infection Masoud Mardani M.D,FIDSA Shahidhid Bh BeheshtiMdi Medical lui Universityit Cytomegalovirus (CMV), Epstein Barr Virus(EBV), Herpes
More information